SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

Hysteria takes hold as schoolgirls fear the needle

By Leave a Comment

smh

Jim O’rourke

March 27, 2011

SCHOOLGIRLS were so frightened and anxious about getting vaccinated against cervical cancer that their reaction ”bordered on hysteria”, a new research paper shows.

The fear was so extreme that girls began crying, screaming and fainting during school vaccination days.

Researchers from the University of Sydney and the Children’s Hospital at Westmead found that when this intense fear was witnessed by classmates waiting to get the needle, anxiety levels jumped even more.

Rwanda: Vaccination Against Cervical Cancer to Begin Soon

By Leave a Comment

Allafrica

The country is set to introduce a new vaccine against Human Papilloma Virus (HPV) that is expected to reduce the number of women dying of cervical cancer.

Diane Mutamba, an official in the Ministry of Health, said that the vaccination is expected to begin next month, with girls in Primary six to be the first beneficiaries.

The vaccine, known as Gardasil, is manufactured by pharmaceutical company, Merck.

Gardasil – Marketplace Dud

By Leave a Comment

lcrtl.blogspot
Friday, March 25, 2011

In 2006, a new vaccine was marketed to supposedly prevent cervical cancer, caused by the human papillomavirus (HPV). In fact the rest of the story is that, Gardasil treats only 2 strains of the more than 100 strains of HPV, and only 2 strains of genital warts. Ponder another fact – according to the Center for Disease Control (CDC), HPV is the most common sexually transmitted disease (STD) in America. Another fact for pondering, is that the immune system of many women is naturally strong enough to clean up the HPV, without any medicine.

Question – Why is a vaccine needed? HPV is an STD, formally known as a venereal disease, a name derived from Venus, the pagan goddess of sexual promiscuity. Sexual behavior, as we know from watching any TV program, has changed over the past 40 years; so too, the number of STDs, which have increased and mutated.

Oh my! Rather than addressing the real problem, which is sexual promiscuity, we have a vaccine to immunize you, rather than moralize you. Add to that, the vaccine doesn’t work on all the strains anyway. Gardasil was fast-tracked without adequate testing. We now know, that there have been many complications and even deaths from the vaccine. Still, it was highly marketed as a miracle drug, probably the greatest discovery since penicillin.

Gardasil: Fear or Facts?

By Leave a Comment

Hudsonspinalhealth

Fear or Facts? On which will you base your decision to vaccinate? While we will not try to convince anyone to get vaccinated or decline vaccination, we do encourage making an educated decision and to NEVER make a major decision out of fear. One of the most disturbing cases of fear-mongering is that which revolves around the Gardasil vaccination. The Gardasil vaccine is targeted to females ages 9-26 in hopes of”preventing” cervical cancer.

Here are some facts you need to know about HPV:

* When detected in the early stages, the HPV virus is easily treated and rarely proceeds to cancer.
* Not all women with HPV develop cervical cancer.
* HPV is just one of several potential causes of cervical cancer.
* At least 50% of sexually active men and women acquire genital HPV infection at some point in their lives — and 90% of the time the virus clears up on its own within two years, and does not lead to cancer.

Safety and Immunogenicity of the Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Men.

By Leave a Comment

Pubmed
J Infect Dis. 2010 Sep 2

Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry JM, Jay N, Aboulafia D, Cohn DL, Einstein MH, Saah A, Mitsuyasu RT, Palefsky JM.

Abstract
Background. Human immunodeficiency virus type 1 (HIV-1)-infected men are at increased risk for anal cancer. Human papillomavirus (HPV) vaccination may prevent anal cancer caused by vaccine types. Methods. AIDS Malignancy Consortium Protocol 052 is a single-arm, open-label, multicenter clinical trial to assess the safety and immunogenicity of the quadrivalent HPV (types 6, 11, 16, and 18) vaccine in HIV-1-infected men. Men with high-grade anal intraepithelial neoplasia or anal cancer by history or by screening cytology or histology were excluded. Men received 0.5 mL intramuscularly at entry, week 8, and week 24. The primary end points were seroconversion to vaccine types at week 28, in men who were seronegative and without anal infection with the relevant HPV type at entry, and grade 3 or higher adverse events related to vaccination. Results. There were no grade 3 or greater adverse events attributable to vaccination among the 109 men who received at least 1 vaccine dose. Seroconversion was observed for all 4 types: type 6 (59 [98%] of 60), type 11 (67 [99%] of 68), type 16 (62 [100%] of 62), and type 18 (74 [95%] of 78). No adverse effects on CD4 counts and plasma HIV-1 RNA levels were observed. Conclusions. The quadrivalent HPV vaccine appears safe and highly immunogenic in HIV-1-infected men. Efficacy studies in HIV-1-infected men are warranted. Clinical trials registration. NCT 00513526 .

PMID: 20812850 [PubMed – as supplied by publisher]

News

Videos

Contact